Dapasmart for Advanced Neuropathic Pain Management
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 14 | $5.11 | $71.58 (0%) | 🛒 Add to cart |
| 28 | $4.28 | $143.16 $119.97 (16%) | 🛒 Add to cart |
| 56 | $3.92 | $286.32 $219.78 (23%) | 🛒 Add to cart |
| 84 | $3.77 | $429.48 $316.57 (26%) | 🛒 Add to cart |
| 112 | $3.55 | $572.64 $397.22 (31%) | 🛒 Add to cart |
| 168 | $3.45
Best per pill | $858.97 $579.70 (33%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 14 | $4.82 | $67.55 (0%) | 🛒 Add to cart |
| 28 | $3.92 | $135.10 $109.89 (19%) | 🛒 Add to cart |
| 56 | $3.60 | $270.19 $201.64 (25%) | 🛒 Add to cart |
| 84 | $3.53 | $405.29 $296.40 (27%) | 🛒 Add to cart |
| 112 | $3.42 | $540.38 $383.11 (29%) | 🛒 Add to cart |
| 168 | $3.25
Best per pill | $810.57 $546.43 (33%) | 🛒 Add to cart |
Synonyms | |||
Dapasmart represents a significant advancement in the therapeutic management of neuropathic pain, offering a targeted approach for patients who have found limited relief with conventional analgesics. As a pregabalin-based medication, it operates by modulating calcium channels in the central nervous system, effectively reducing the hyperexcitability of neurons that characterizes neuropathic conditions. This product card provides a comprehensive, expert-level overview of Dapasmart, detailing its pharmacological profile, appropriate usage, and critical safety information to ensure optimal patient outcomes. It is essential for prescribing clinicians to review this information in conjunction with the full prescribing information and current clinical guidelines.
Features
- Active Pharmaceutical Ingredient: Pregabalin
- Standard Dosage Strengths: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg film-coated tablets
- Pharmacotherapeutic Classification: Antiepileptic drug; Analgesic
- Mechanism of Action: Binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system
- Bioavailability: ≥90% and independent of food intake
- Time to Peak Plasma Concentration (Tmax): Approximately 1.5 hours post-administration
- Elimination Half-Life: Approximately 6.3 hours
- Primary Route of Excretion: Renal (approximately 90% of the dose recovered in urine as unchanged pregabalin)
Benefits
- Provides significant reduction in pain scores associated with diabetic peripheral neuropathy and postherpetic neuralgia, as demonstrated in multiple randomized controlled trials.
- Improves patient-reported outcomes, including sleep interference scores and overall quality of life, by addressing the central sensitization component of chronic pain.
- Offers a predictable pharmacokinetic profile with linear absorption, allowing for straightforward dose titration and management.
- Serves as an effective adjunctive therapy for adult patients with partial onset seizures, contributing to a comprehensive seizure management plan.
- Facilitates flexible dosing regimens with multiple available strengths to accommodate individual patient tolerance and therapeutic response.
Common use
Dapasmart (pregabalin) is primarily indicated for the management of neuropathic pain. Its most common applications include the treatment of pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). In clinical neurology and pain management, it is also approved for use as adjunctive therapy in the treatment of partial-onset seizures in adults. Its efficacy stems from its ability to calm hyperexcited neurons, which is the pathological hallmark of these conditions. It is not indicated for the treatment of acute, inflammatory, or nociceptive pain (e.g., postoperative pain, headaches, arthritic pain) and should not be used as a first-line analgesic for these purposes.
Dosage and direction
Dosage must be individualized according to the patient’s renal function and therapeutic response. Dapasmart is administered orally with or without food.
- Neuropathic Pain (DPN/PHN): The initial dose is 150 mg per day, administered in two or three divided doses (e.g., 75 mg twice daily or 50 mg three times daily). Based on efficacy and tolerability, the dose may be increased to 300 mg/day within one week. If needed, and if tolerated, the dose may be further increased to a maximum of 600 mg/day after an additional week. The maximum recommended dose is 600 mg/day.
- Adjunctive Therapy for Epilepsy: The initial dose is 150 mg/day, given in two or three divided doses. Based on individual response and tolerability, the dose may be increased to a maximum of 600 mg/day.
- Patients with Renal Impairment: Dosage adjustment is critical. The daily dose should be reduced based on creatinine clearance (CrCl). Please consult the full prescribing information for detailed dosing tables in renal impairment.
- Discontinuation: To minimize the potential for increased seizure frequency or withdrawal symptoms, Dapasmart should be tapered gradually over a minimum of one week. Abrupt discontinuation is not recommended.
Precautions
- Dizziness and Somnolence: Dapasmart may cause dizziness and drowsiness, which could increase the risk of accidental injury. Patients should be advised not to drive, operate complex machinery, or engage in other hazardous activities until they have sufficient experience with the drug to gauge its effect on their mental and motor performance.
- Peripheral Edema: Monitor patients for signs of peripheral edema, which may or may not be associated with weight gain. Caution is advised in patients with pre-existing cardiac conditions or those taking drugs associated with edema (e.g., thiazolidinediones).
- Weight Gain: Weight gain has been observed with pregabalin use. Patients should be monitored for this effect, and appropriate dietary and lifestyle advice should be given.
- Ophthalmological Effects: Blurred vision and other visual disturbances have been reported. Patients should be instructed to inform their physician if any changes in vision occur.
- Suicidal Behavior and Ideation: Antiepileptic drugs, including pregabalin, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients, their caregivers, and families should be alert to the emergence or worsening of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Any concerning behaviors should be reported immediately to a healthcare provider.
Contraindications
Dapasmart is contraindicated in patients with known hypersensitivity to pregabalin or any of the excipients listed in the product formulation. A history of angioedema with previous pregabalin use is an absolute contraindication for future use.
Possible side effect
Adverse reactions are generally dose-related. The most commonly observed side effects (≥5% and twice the rate of placebo) are:
- Very Common (≥1/10): Dizziness, somnolence.
- Common (≥1/100 to <1/10): Increased appetite, euphoric mood, confusion, libido decreased, irritability, ataxia, attention disturbance, coordination abnormal, memory impairment, tremor, dysarthria, paresthesia, sedation, blurred vision, diplopia, vertigo, dry mouth, constipation, vomiting, flatulence, erectile dysfunction, fatigue, peripheral edema, feeling drunk, gait disturbance, weight increase.
- Additional side effects are documented in the full prescribing information. This is not an exhaustive list.
Drug interaction
- CNS Depressants: Dapasmart may potentiate the effects of ethanol and other drugs that cause dizziness, somnolence, or cognitive and motor dysfunction (e.g., benzodiazepines, opioids, barbiturates, sedating antihistamines). Additive effects on cognitive and motor function are expected. Dose adjustments may be necessary.
- Gabapentin: Concomitant use is not recommended as both drugs share a similar mechanism of action, increasing the risk of adverse effects without evidence of enhanced efficacy.
- Pioglitazone and other Thiazolidinediones: Caution is advised due to the potential for an additive effect on peripheral edema and weight gain.
- No Known Pharmacokinetic Interactions: Pregabalin is not metabolized in the liver and does not inhibit or induce liver enzymes (e.g., CYP450 isozymes). It is eliminated renally. Therefore, it is unlikely to be involved in pharmacokinetic interactions with other drugs metabolized by these pathways.
Missed dose
If a patient misses a dose, they should take it as soon as they remember, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule should be resumed. The patient should not take a double dose to make up for a missed one.
Overdose
There is no specific antidote for pregabalin overdose. In cases of suspected overdose, standard supportive measures should be initiated as clinically indicated. Pregabalin can be removed from the serum by hemodialysis (4-hour hemodialysis session removes approximately 50% of the drug). The patient’s airway should be protected, and hemodynamic and respiratory monitoring should be provided. Contact a poison control center for the most current guidance on management.
Storage
Store Dapasmart tablets at room temperature (20°C to 25°C / 68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the medication in its original blister pack or bottle to protect it from light and moisture. Keep all medications out of the reach of children and pets.
Disclaimer
This product card is intended for healthcare professionals and contains summary information. It is not a substitute for the full prescribing information, which contains more detailed data on clinical trials, adverse reactions, and specific patient populations. The prescriber should consult the official local prescribing information and relevant clinical guidelines before initiating therapy. The information contained herein is based on the product’s characteristics at the time of writing and may be subject to change.
Reviews
- “In my practice, Dapasmart has become a cornerstone for managing refractory neuropathic pain. Its predictable titration and efficacy, particularly in diabetic neuropathy, are superior to many previous options. The main challenge remains managing somnolence during the initial titration phase.” – Neurologist, 15 years of experience
- “As a pain specialist, I find the multiple dosage strengths of Dapasmart invaluable for customizing treatment. It allows for very fine-tuned adjustments, which is critical for elderly patients or those with comorbidities. The improvement in sleep quality for my PHN patients is often remarkable.” – Pain Management Specialist
- “While effective, patient education is paramount. I spend considerable time setting expectations about side effects like dizziness and weight gain. For informed and motivated patients, Dapasmart can be a life-changing therapy that restores function.” – Clinical Pharmacist specializing in ambulatory care
- “The robust data from clinical trials gives me confidence in prescribing Dapasmart. The clear renal dosing adjustments are a critical feature that is well-outlined, ensuring safe use in a wide demographic.” – Internal Medicine Physician